Research advances in current drugs targeting hyperlipidemia (Review).
Zhao H, Wang Y, Li Y, Cheng R, Chen W.
Mol Med Rep. 2025 Oct;32(4):258. doi: 10.3892/mmr.2025.13623. Epub 2025 Jul 19.
Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?
Martin SS.
Atherosclerosis. 2018 Oct;277:172-174. doi: 10.1016/j.atherosclerosis.2018.07.034. Epub 2018 Jul 27.
Familial combined hyperlipidemia and insulin resistance : distant relatives linked by intra-abdominal fat?
Eckel RH.
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):469-70. doi: 10.1161/01.atv.21.4.469.
Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.
Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R; Atherosclerosis and Metabolic Diseases Study Group.
Vasc Health Risk Manag. 2007;3(6):877-86.
Hyperlipidemia in children.
McCrindle BW.
Thromb Res. 2006;118(1):49-58. doi: 10.1016/j.thromres.2005.01.006. Epub 2005 Feb 17.
Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia.
Pedro-Botet J, Climent E, Gabarró N, Millán J.
Clin Investig Arterioscler. 2021 May;33 Suppl 2:43-49. doi: 10.1016/j.arteri.2020.12.013.
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Ayyobi AF, Brunzell JD.
Am J Cardiol. 2003 Aug 18;92(4A):27J-33J. doi: 10.1016/s0002-9149(03)00613-1.
New Therapies for Primary Hyperlipidemia.
Aguilar-Salinas CA, Gómez-Díaz RA, Corral P.
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1216-1224. doi: 10.1210/clinem/dgab876.
Rare and common mutations in hyperlipidemia and atherosclerosis. With special reference to familial defective apolipoprotein B-100.
Tybjaerg-Hansen A.
Scand J Clin Lab Invest Suppl. 1995;220:57-76.
Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass.
Keulen ET, Voors-Pette C, de Bruin TW.
Am J Hypertens. 2001 Apr;14(4 Pt 1):357-63. doi: 10.1016/s0895-7061(00)01280-2.
